Febuxostat Patent Expiration
Febuxostat is Used for managing hyperuricemia in patients with gout. It was first introduced by Takeda Pharmaceuticals Usa Inc
Febuxostat Patents
Given below is the list of patents protecting Febuxostat, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Uloric | US8372872 | Methods for concomitant treatment of theophylline and febuxostat | Sep 08, 2031 | Takeda Pharms Usa |
| Uloric | US9107912 | Methods for concomitant treatment of theophylline and febuxostat | Sep 08, 2031 | Takeda Pharms Usa |
| Uloric | US7361676 | Solid preparation containing single crystal form |
Mar 08, 2024
(Expired) | Takeda Pharms Usa |
| Uloric | US6225474 | Polymorphs of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and method of producing the same |
Jun 18, 2019
(Expired) | Takeda Pharms Usa |
| Uloric | US5614520 | 2-arylthiazole derivatives and pharmaceutical composition thereof |
Mar 25, 2019
(Expired) | Takeda Pharms Usa |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Febuxostat's patents.
Latest Legal Activities on Febuxostat's Patents
Given below is the list recent legal activities going on the following patents of Febuxostat.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 12 Aug, 2024 | US8372872 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 Feb, 2023 | US9107912 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 12 Aug, 2020 | US8372872 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 01 Oct, 2019 | US7361676(Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 18 Feb, 2019 | US9107912 |
| Email Notification Critical
| 30 Jan, 2019 | US9107912 |
| Change in Power of Attorney (May Include Associate POA) Critical
| 30 Jan, 2019 | US9107912 |
| Correspondence Address Change Critical
| 29 Jan, 2019 | US9107912 |
| Change in Power of Attorney (May Include Associate POA) Critical
| 10 Sep, 2018 | US8372872 |
| Email Notification Critical
| 10 Sep, 2018 | US8372872 |
Febuxostat's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Febuxostat:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Tigulixostat (IBI128) vs Febuxostat in Gout | Innovent Biologics Technology Limited (Shanghai R&D Center) | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE3 |
| Clinical Study to Evaluate the Efficacy of Febuxostat in the Treatment of Conservatively Managed Intracranial Hemorrhage Patients | Tanta University | NA |
RECRUITING
(Jul 1, 2026)
| PHASE2 |
| Boosting Osimertinib Blood Brain Barrier Penetration | Maastricht University Medical Center | NA |
RECRUITING
(Jun 1, 2026)
| PHASE2 |
| A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients | JW Pharmaceutical | NA |
COMPLETED
(Apr 1, 2026)
| PHASE3 |